Role of i.v.allopurinol and rasburicase in tumor lysis syndrome

November 2003
American Journal of Health-System Pharmacy;11/1/2003, Vol. 60 Issue 21, p2223
Academic Journal
Presents information about the role of developed drugs, i.v.allopurinol and rasburicase in tumor lysis syndrome. Information regarding the origins and limitations of standard therapy for the prevention of the disease; Effects of the drugs in the treatment of the disease; Comparison with other therapy for the prevention of the disease.


Related Articles

  • Role of i.v.allopurinol and rasburicase in tumor lysis syndrome. Hooldsworth, Mark T.; Nguyen, Phuongthao // American Journal of Health-System Pharmacy;11/1/2003, Vol. 60 Issue 21, p2213 

    The role of i.v. allopurinol and rasburicase in tumor lysis syndrome (TLS) is described. The current standard management for TLS consists of oral allopurinol in conjunction with i.v. hydration with or without alkalinization. Despite this standard prophylactic regimen, some high-risk patients may...

  • Rational Use of Generic Psychotropic Drugs. Carbon, Maren; Correll, Christoph // CNS Drugs;2013, Vol. 27 Issue 5, p353 

    For economic reasons, the generic substitution of branded medications is common and welcome. These replacements are based on the concept of bioequivalence, which is considered equal to therapeutic equivalence. Regulatory standards for bioequivalence require the 90 % confidence intervals of group...

  • TÃœRKÄ°YE'DE VE DÃœNYADA AKILCI Ä°LAÇ KULLANIMI. YILMAZTÜRK, Aysun // Kastamonu University Journal of Economics & Administrative Scien;Jun2013, Vol. 2 Issue 1, p42 

    Drug use health care services in which we live in the most important part of presentation. Pioneering new developments in medical treatment and a combination of diseases cause an increase in drug consumption. It is possible that used to take up to non-treatment diseases treatment, in order to...

  • The Incidence of Over-the-counter Medication Use in Patients with Midgut Neuroendocrine Tumors. LINDHOLM, ERIKA B.; GUPTA, MANEESH K.; BOUDREAUX, J. P.; BURNS, LEIGH ANN; WANG, YI Z.; WOLTERING, EUGENE A. // American Surgeon;Mar2015, Vol. 81 Issue 3, p278 

    Recent increases in the use of over-the-counter (OTC) medicines and the underreporting of the use of these medications to physicians have sparked interest in the number and types of "supportive" therapies used by patients with neuroendocrine tumors (NETS). Patients with NETS are of special...

  • Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice. Parulekar, Wendy R.; Eisenhauer, Elizabeth A. // JNCI: Journal of the National Cancer Institute;7/7/2004, Vol. 96 Issue 13, p990 

    Background: New targeted, non-cytotoxic anticancer agents, such as small-molecule kinase inhibitors, pose challenges to the current phase I paradigm of dose selection based on toxicity. Moreover, increasing the drug dose to toxicity may be unnecessary for drug effect, making the use of maximum...

  • EXPANDING OPTIONS: Novel melanoma therapies portend a 'golden age' of cancer care. Moyer, Paula // Dermatology Times;May2012, Vol. 33 Issue 5, p39 

    The article reports on the significant roles of vemurafenib and ipilimumab in the treatment of melanoma. It presents the views of melanoma experts Adil Daub, Edward S. McClay, and Arkadiusz Dudek regarding the effectiveness of the newly approved drugs. McClay states that vemurafenib is designed...

  • Biologic strategies. Jesitus, John // Dermatology Times;Apr2012, Vol. 33 Issue 4, p34 

    The article focuses on the need for physicians to consider treatment options for nonmelanoma skin cancer patients taking biologic drugs for psoriasis as a case-by-case basis. According to Doctor Oscar Colegio of Yale School of Medicine, tumor necrosis factor (TNF)-alpha inhibitor agents such as...

  • Amgen Invests in Nanomedicine with BIND Biosciences Collaboration. Cartwright, Heather // PharmaDeals Review;2013, Vol. 2013 Issue 1, p8 

    The article reports that U.S.-based biopharmaceutical company BIND Biosciences has partnered with Amgen to commercialise and develop a new class of therapeutics Accurinsâ„¢ kinase inhibitor nanomedicine for the management of solid tumours. It states that the partnership is figured to improve...

  • Development of Rational Drug Combinations with Investigational Targeted Agents. Clark, Adam; Ellis, Matthew; Erlichman, Charles; Lutzker, Stuart; Zwiebel, James // Oncologist;May2010, Vol. 15 Issue 5, p496 

    The article focuses on an alternative regulatory process to the combination rule in drug development. It states several benefits of the alternative model such as the potential for combination therapies to synergistically target tumors. It mentions the 2new molecular entity (NME) strategy which...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics